Effectiveness of Centchroman on  Regression of Fibroadenosis and  Mastalgia

Rajswaroob, Udayakumar; Kannan, Rajendiran; Kannan, Narayanasamy Subbaraju; Tirouaroul, T

doi:10.7860/jcdr/2016/20108.8604

Cited by 7 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical presentations in initial visit showed maximum respondent had cyclical mastalgia (57.78%) and 42.22% had non-cyclical mastalgia. Similar observation was noted in a previous study by Rajswaroob et al 17 and Nirhale et al 8 In this study maximum respondents (60%) had both breasts involvement, 26.7% had left breast and 13.3% had right breast involvement. In a previous study by Sangma MB et al 18 observed maximum respondents had right breast involvement (48%), the left breast was affected in 40% patients while only 12% cases both breasts were affected, that differs from our observation.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Response to different medical treatment options for mastalgia in fibrocystic breast disease

Mostary¹,

Khan

Hossain

et al. 2021

Birdem Med J

View full text Add to dashboard Cite

Background: Fibrocystic breast disease is the most common type of benign breast disease and mastalgia is the most common symptom of fibrocystic breast disease. Various types of medical management are given as a gold standard treatment for that. The aim of this study was to compare the effects of different commonly used medical management options of mastalgia of fibrocystic breast disease on the quality of life of patients and their side effects as well. Methods: This quasi-experimental study was carried out in Out-patients Department of General Surgery, BIRDEM General Hospital, Dhaka, from July 2018 to June 2019. Total 45 patients with fibrocystic breast disease were selected according to the eligibility criteria and were allocated to two groups by alternative random selection. In non-pharmacological treatments receiving group, lifestyle modification advices along with evening primrose oil were given. On the other hand, in pharmacological treatment receiving group, bromocriptine and danazole were given according to some selection criteria of the patients. Response of treatments to each group and side effects were determined at one month, three months and six months follow-up respectively. Mastalgia was measured by visual analogue scale (VAS) score and quality of life was calculated by modified WHO-QOL scoring in each follow-up. Results: Patients had an average age of 30.24±6.93 years with a majority in the age group 31-35 years (33.3%). Most patients were married (64.4%), housewives (62.20%), from middle-class groups (62.20%), multiparous (57.78%) and the majority had absence of the family history of breast diseases (84.45%). Majority of them presented with cyclical mastalgia (57.78%), bilateral mastalgia (60%) and mastalgia with lumpiness (44.4%). Among the patients who received non-pharmacological treatment, mastalgia improved in 34.78% cases and patients received pharmacological treatment, mastalgia improved in 72.73% cases. Different domains of quality of life were improved significantly in patients who received pharmacological treatment. Though majority of the patients had side effects due to pharmacological treatment, they were well tolerated. Conclusion: Despite having various side effects, pharmacological management by danazol or bromocriptine was well tolerated to our patients and a dramatic improvement was observed on quality of life than the nonpharmacologically treated patients. BIRDEM Med J 2022; 12(1): 22-29

show abstract

Section: Discussionsupporting

confidence: 92%

“…Almost similar observation was seen in some previous study by Rajswaroob et al 17 and Neogi P et al 21 and Nirhale et al 8 There are some limitations of our study. This study was performed in a single tertiary care hospital among small available population size.…”

Section: Discussionsupporting

confidence: 88%

Response to different medical treatment options for mastalgia in fibrocystic breast disease

Mostary¹,

Khan

Hossain

et al. 2021

Birdem Med J

View full text Add to dashboard Cite

show abstract

“…In this case, a single patient occasionally complained of several adverse symptoms. In several earlier research by Rajswaroob et al [18] , Neogi et al [19] and Nirhale et al [20] , a nearly same observation is made. In our study, the reported side effects due to Primrose use were comparable to Mostary et al [21] who reported bloating in 6.7% and headache in 2.2% of patients treated with primrose.…”

Section: Discussionsupporting

confidence: 65%

Vitamin E versus Evening Primrose Oil versus Placebo for the Treatment of Cyclic Mastalgia: A Double-Blind Randomized Controlled Trial

Seifalyazal¹,

Albalkiny²,

Fawzy³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Reassurance is important because it influences lifestyle choices or fears of breast cancer in 70% of women of reproductive age who have breast discomfort and seek medical attention. Either cyclic or noncyclic mastalgia exists. Breast discomfort needs to be carefully evaluated and should be looked into the same way as any other breast symptom. Natural remedies like evening primrose oil and vitamin E are now being used as therapeutic options because of the undesirable side effects of other treatment approaches. Objective: In order to treat cyclic mastalgia, we compared the efficacy and adverse effects of vitamin E and evening primrose oil. Patients and Methods: We conducted a double-blind randomized controlled trial between February 2018 and February 2019 at Al-Jedaani Hospitals, KSA. A total of 160 women of reproductive age with a chief complaint of cyclic mastalgia were enrolled into this study. They were randomly assigned into 3 groups: group A of 55 patients (34.4%) received vitamin E, group B of 45 patients (28.1%) received evening primrose oil and group C of 60 patients (37.5%) received placebo. Overall pain severity and the effect of pain on patients' lifestyle were assessed at 1-month and 3-month follow-up visits. ResultsThe mean age of the patients was 31.23 ± 6.82 years. Highest respondents were aged between 30 and 38 years (34.5%). The median pain score and the effect of pain on patients' lifestyle were significantly decreased on successive follow-up visits. Although this decrease was significant in each individual group, it was not statistically significant compared to one another (P value = 0.619 and 0.621 respectively). Conclusion Vitamin E and evening primrose oil have a good impact on cyclic breast pain but their effect is not much different than placebo effect

show abstract

“…Selective estrogen receptor modulators (SERMs) like tamoxifen and Ormeloxifene have been shown to improve the signs and symptoms of FCD. Other types of hormonal agents that have been considered for control of FCD include analogs of luteinizing hormone-releasing hormone, Gestrinone tablets, and different forms of progestin [19,20]. Also, evening primrose oil, Vitamin B6 [21], and Vitamin E [22] have caused moderate improvement in FCD.…”

Section: Discussionmentioning

confidence: 99%

Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial

et al. 2021

View full text Add to dashboard Cite

Effectiveness of Centchroman on Regression of Fibroadenosis and Mastalgia

Cited by 7 publications

References 39 publications

Response to different medical treatment options for mastalgia in fibrocystic breast disease

Response to different medical treatment options for mastalgia in fibrocystic breast disease

Vitamin E versus Evening Primrose Oil versus Placebo for the Treatment of Cyclic Mastalgia: A Double-Blind Randomized Controlled Trial

Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial

Contact Info

Product

Resources

About